Zoledronic Acid · Regulatory label update

FDA supplemental approval: Zoledronic Acid (Labeling)

U.S. Food and Drug Administration · April 15, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

This is an FDA supplemental approval for a zoledronic acid labeling change (ANDA supplement filed by Mylan Labs Ltd, approved 15 April 2026). The record confirms regulatory authorization but does not contain or report clinical trial data, efficacy outcomes, or safety findings.

What was studied

Regulatory label update.

Key findings

Safety

This is a regulatory approval record only; it does not contain clinical trial results, efficacy data, or safety summaries.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

FDA supplemental approval for zoledronic acid labeling change; does not report clinical trial outcomes or comparative efficacy.

Caveats

This is a regulatory approval record only; it does not contain clinical trial results, efficacy data, or safety summaries.
The specific labeling changes are not described in this source.
No comparative data, sample size, or outcome measures are provided.
Clinical evidence supporting the labeling change is not reported in this record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory action record; no clinical study design reported.

Directness

insufficient

Labeling supplement; clinical outcomes not described in source.

Consistency

insufficient

Single regulatory action; no comparative data or replication reported.

Risk of bias

insufficient

Regulatory approval document; trial methodology not documented here.

Sample adequacy

insufficient

No clinical trial sample size or population data in source.

What is missing. This record has no key findings, reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

Drugs@FDA record for application ANDA205254. This is a regulatory action record, not a clinical study. Brand name: ZOLEDRONIC ACID. Active ingredient: ZOLEDRONIC ACID. Sponsor: MYLAN LABS LTD. Submission type: SUPPL (supplement). Submission class: Labeling. Approval status date: 2026-04-15. Products: ZOLEDRONIC ACID, INJECTABLE, INTRAVENOUS, ZOLEDRONIC ACID EQ 5MG BASE/100ML.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Mylan LabsZoledronic Acid